NASDAQ:TSHA Taysha Gene Therapies (TSHA) Stock Price, News & Analysis $1.83 -0.02 (-1.08%) (As of 05:45 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Taysha Gene Therapies Stock (NASDAQ:TSHA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Taysha Gene Therapies alerts:Sign Up Key Stats Today's Range$1.78▼$1.8850-Day Range$1.27▼$3.2452-Week Range$1.19▼$4.32Volume1.54 million shsAverage Volume2.86 million shsMarket Capitalization$375.05 millionP/E Ratio2.90Dividend YieldN/APrice Target$6.63Consensus RatingBuy Company OverviewTaysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.Read More… Taysha Gene Therapies Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks75th Percentile Overall ScoreTSHA MarketRank™: Taysha Gene Therapies scored higher than 75% of companies evaluated by MarketBeat, and ranked 252nd out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingBuy Consensus RatingTaysha Gene Therapies has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageTaysha Gene Therapies has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Taysha Gene Therapies' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Taysha Gene Therapies are expected to decrease in the coming year, from ($0.35) to ($0.36) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Taysha Gene Therapies is 2.90, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 112.39.Price to Earnings Ratio vs. SectorThe P/E ratio of Taysha Gene Therapies is 2.90, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 87.20.Price to Book Value per Share RatioTaysha Gene Therapies has a P/B Ratio of 4.58. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted7.65% of the outstanding shares of Taysha Gene Therapies have been sold short.Short Interest Ratio / Days to CoverTaysha Gene Therapies has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Taysha Gene Therapies has recently decreased by 0.51%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTaysha Gene Therapies does not currently pay a dividend.Dividend GrowthTaysha Gene Therapies does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted7.65% of the outstanding shares of Taysha Gene Therapies have been sold short.Short Interest Ratio / Days to CoverTaysha Gene Therapies has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Taysha Gene Therapies has recently decreased by 0.51%, indicating that investor sentiment is improving. News and Social Media2.7 / 5News SentimentN/A News SentimentTaysha Gene Therapies has a news sentiment score of 0.90. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Taysha Gene Therapies this week, compared to 3 articles on an average week.Search InterestOnly 2 people have searched for TSHA on MarketBeat in the last 30 days. This is a decrease of -85% compared to the previous 30 days.MarketBeat Follows6 people have added Taysha Gene Therapies to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Taysha Gene Therapies insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.70% of the stock of Taysha Gene Therapies is held by insiders.Percentage Held by Institutions77.70% of the stock of Taysha Gene Therapies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Taysha Gene Therapies' insider trading history. Receive TSHA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Taysha Gene Therapies and its competitors with MarketBeat's FREE daily newsletter. Email Address TSHA Stock News HeadlinesTaysha Gene Therapies files for $300M mixed shelf offeringDecember 14, 2024 | msn.comTaysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)December 6, 2024 | globenewswire.comWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.December 23, 2024 | Behind the Markets (Ad)Taysha Gene Therapies' SWOT analysis: stock poised for growth in Rett syndrome marketNovember 27, 2024 | uk.investing.comBuy Rating for Taysha Gene Therapies Due to Safer Administration Method and Lower Viral DoseNovember 21, 2024 | markets.businessinsider.comQ3 2024 Taysha Gene Therapies Inc Earnings CallNovember 14, 2024 | finance.yahoo.comTaysha Gene Therapies: Promising Progress and Financial Stability Justify Buy RatingNovember 14, 2024 | markets.businessinsider.comBuy Rating Justified for Taysha Gene Therapies Amid Promising TSHA-102 Developments and Upcoming CatalystsNovember 14, 2024 | markets.businessinsider.comSee More Headlines TSHA Stock Analysis - Frequently Asked Questions How have TSHA shares performed this year? Taysha Gene Therapies' stock was trading at $1.77 at the beginning of the year. Since then, TSHA shares have increased by 3.4% and is now trading at $1.83. View the best growth stocks for 2024 here. How were Taysha Gene Therapies' earnings last quarter? Taysha Gene Therapies, Inc. (NASDAQ:TSHA) issued its quarterly earnings data on Monday, August, 12th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.10) by $0.01. The company earned $1.11 million during the quarter, compared to analyst estimates of $3.62 million. Taysha Gene Therapies had a negative net margin of 229.67% and a negative trailing twelve-month return on equity of 106.36%. When did Taysha Gene Therapies IPO? Taysha Gene Therapies (TSHA) raised $125 million in an IPO on Thursday, September 24th 2020. The company issued 6,600,000 shares at $18.00-$20.00 per share. Goldman Sachs, Morgan Stanley and Jefferies acted as the underwriters for the IPO and Chardan was co-manager. Who are Taysha Gene Therapies' major shareholders? Top institutional shareholders of Taysha Gene Therapies include FMR LLC (9.11%), RTW Investments LP (7.29%), Geode Capital Management LLC (1.74%) and State Street Corp (1.69%). Insiders that own company stock include RA Session II, Sean P Nolan, Paul B Manning, Suyash Prasad, Kamran Alam, Sukumar Nagendran and Phillip B Donenberg. View institutional ownership trends. How do I buy shares of Taysha Gene Therapies? Shares of TSHA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Taysha Gene Therapies own? Based on aggregate information from My MarketBeat watchlists, some other companies that Taysha Gene Therapies investors own include Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Alphabet (GOOG), Visa (V) and Walt Disney (DIS). Company Calendar Last Earnings8/12/2024Today12/23/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TSHA CUSIPN/A CIK1806310 Webwww.tayshagtx.com Phone214-612-0000FaxN/AEmployees180Year Founded2020Price Target and Rating Average Stock Price Target$6.63 High Stock Price Target$8.00 Low Stock Price Target$5.00 Potential Upside/Downside+263.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)$0.63 Trailing P/E Ratio2.90 Forward P/E RatioN/A P/E GrowthN/ANet Income$-111,570,000.00 Net Margins-229.67% Pretax Margin-229.67% Return on Equity-106.36% Return on Assets-49.16% Debt Debt-to-Equity Ratio0.48 Current Ratio5.51 Quick Ratio5.51 Sales & Book Value Annual Sales$9.92 million Price / Sales37.72 Cash FlowN/A Price / Cash FlowN/A Book Value$0.40 per share Price / Book4.56Miscellaneous Outstanding Shares204,943,000Free Float199,410,000Market Cap$374.02 million OptionableOptionable Beta0.79 Social Links (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report This page (NASDAQ:TSHA) was last updated on 12/23/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Taysha Gene Therapies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Taysha Gene Therapies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.